Targeting atherosclerotic inflammation: Advances in NLRP3 inflammasome inhibitors beyond LDL-C
By: Ligang Bao and Xialing Dai
References
- J. Pedro-Botet, E. Climent and D. Benaiges, El colesterol LDL como agente causal de la aterosclerosis [LDL cholesterol as a causal agent of atherosclerosis], Clin. Invest. Arterioscler. 36(Suppl. 1) (2024) S3-S8; https://doi.org/10.1016/j.arteri.2024.07.001
- C. Guijarro and J. Cosín-Sales, Colesterol LDL y aterosclerosis: evidencias [LDL cholesterol and atherosclerosis: The evidence], Clin. Invest. Arterioscler. 33(Suppl. 1) (2021) 25–32; https://doi.org/10.1016/j.arteri.2020.12.004
- B. Z. Shao, H. Y. Xu, Y. C. Zhao, X. R. Zheng, F. Wang and G. R. Zhao, NLRP3 inflammasome in atherosclerosis: Putting out the fire of inflammation, Inflammation 46(1) (2023) 35–46; https://doi.org/10.1007/s10753-022-01725-x
- A. Liaqat, M. Asad, F. Shoukat and A. U. Khan, A spotlight on the underlying activation mechanisms of the NLRP3 inflammasome and its role in atherosclerosis: A review, Inflammation 43(6) (2020) 2011–2020; https://doi.org/10.1007/s10753-020-01290-1
- M. Yalcinkaya and A. R. Tall, Cholesterol crystals as triggers of NLRP3 inflammasome activation in atherosclerosis, Curr. Atheroscler. Rep. 27(1) (2025) Article ID 77 (9 pages); https://doi.org/10.1007/s11883-025-01323-w
- M. Takahashi, NLRP3 inflammasome as a common denominator of atherosclerosis and abdominal aortic aneurysm, Circ. J. 85(12) (2021) 2129-2136; https://doi.org/10.1253/circj.CJ-21-0258.
- S. I. S. Al-Hawary, S. A. Jasim, R. M. Romero-Parra, G. S. Bustani, A. Hjazi, M. I. Alghamdi, A. K. Kareem, E. R. Alwaily, R. S. Zabibah, J. Gupta, R. Mahmoudi and S. Hosseini-Fard, NLRP3 inflammasome pathway in atherosclerosis: Focusing on the therapeutic potential of non-coding RNAs, Pathol. Res. Pract. 246 (2023) Article ID 154490; https://doi.org/10.1016/j.prp.2023.154490
- J. Hettwer, J. Hinterdobler, B. Miritsch, M. A. Deutsch, X. Li, C. Mauersberger, A. Moggio, Q. Braster, H. Gram, A. A. B. Robertson, M. A. Cooper, O. Groß, M. Krane, C. Weber, W. Koenig, O. Soehnlein, N. H. Adamstein, P. Ridker, H. Schunkert, P. Libby, T. Kessler and H. B. Sager, Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis, Cardiovasc. Res. 118(13) (2022) 2778–2791; https://doi.org/10.1093/cvr/cvab337
- Y. Qin and W. Zhao, Posttranslational modifications of NLRP3 and their regulatory roles in inflammasome activation, Eur. J. Immunol. 53(10) (2023) e2350382 (9 pages); https://doi.org/10.1002/eji.202350382
- R. Yuan, W. Zhang, P. Nie, K. Lan, X. Yang, A. Yin, Q. Xiao, Y. Shen, K. Xu, X. Wang, X. Pan, L. Shen and B. He, Nur77 deficiency exacerbates macrophage NLRP3 inflammasome-mediated inflammation and accelerates atherosclerosis, Oxid. Med. Cell. Longev. 2022(1) (2022) Article ID 2017815 (14 pages); https://doi.org/10.1155/2022/2017815
- S. Chen, Y. Wang, Y. Pan, Y. Liu, S. Zheng, K. Ding, K. Mu, Y. Yuan, Z. Li, H. Song, Y. Jin and J. Fu, Novel role for tranilast in regulating NLRP3 ubiquitination, vascular inflammation, and atherosclerosis, J. Am. Heart Assoc. 9(12) (2020) e015513; https://doi.org/10.1161/jaha.119.015513
- V. Agarwal, R. Haldhar, A. H. Hirad, B. Ahmed, S. B. Han, A. Gupta, V. Raj and S. Lee, Repurposing FDA-approved drugs as NLRP3 inhibitors against inflammatory diseases: machine learning and molecular simulation approaches, J. Biomol. Struct. Dyn. 43(8) (2025) 4327–4339; https://doi.org/10.1080/07391102.2024.2308072
- J. Zhao, Z. Wang, Z. Yuan, S. Lv and Q. Su, Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice, Diab. Vasc. Dis. Res. 17(6) (2020) Article ID 1479164120977441 (10 pages); https://doi.org/10.1177/1479164120977441
- J. Luo, X. Wang, X. Jiang, C. Liu, Y. Li, X. Han, X. Zuo, Y. Li, N. Li, Y. Xu and S. Si, Rutaecarpine derivative R3 attenuates atherosclerosis via inhibiting NLRP3 inflammasome-related inflammation and modulating cholesterol transport, FASEB J. 34(1) (2020) 1398–1411; https://doi.org/10.1096/fj.201900903RRR
- B. Ahmad, A. Achek, M. Farooq and S. Choi, Accelerated NLRP3 inflammasome-inhibitory peptide design using a recurrent neural network model and molecular dynamics simulations, Comput. Struct. Biotechnol. J. 21 (2023) 4825–4835; https://doi.org/10.1016/j.csbj.2023.09.038
- L. Y. El-Sharkawy, D. Brough and S. Freeman, Inhibiting the NLRP3 inflammasome, Molecules 25(23) (2020) Article ID 5533 (14 pages); https://doi.org/10.3390/molecules25235533
- H. Sharif, L. Wang, W. L. Wang, V. G. Magupalli, L. Andreeva, Q. Qiao, A. V. Hauenstein, Z. Wu, G. Núñez, Y. Mao and H. Wu, Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome, Nature 570(7761) (2019) 338–343; https://doi.org/10.1038/s41586-019-1295-z
- Y. Duan, L. Zhang, D. Angosto-Bazarra, P. Pelegrín, G. Núñez and Y. He, RACK1 mediates NLRP3 Inflammasome activation by promoting NLRP3 active conformation and inflammasome assembly, Cell Rep. 33(7) (2020) Article ID 108405 (11 pages + e5); https://doi.org/10.1016/j.celrep.2020.108405
- Y. Shi, Q. Lv, M. Zheng, H. Sun and F. Shi, NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages, Int. Immunopharmacol. 92 (2021) Article ID 107358 (11 pages); https://doi.org/10.1016/j.intimp.2020.107358
- G. Ren, X. Zhang, Y. Xiao, W. Zhang, Y. Wang, W. Ma, X. Wang, P. Song, L. Lai, H. Chen, Y. Zhan, J. Zhang, M. Yu, C. Ge, C. Li, R. Yin and X. Yang, ABRO1 promotes NLRP3 inflammasome activation through regulation of NLRP3 deubiquitination, EMBO J. 38(6) (2019) e100376 (17 pages); https://doi.org/10.15252/embj.2018100376
- Y. Yang, H. Wang, M. Kouadir, H. Song and F. Shi, Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors, Cell Death Dis. 10(2) (2019) Article ID 128 (11 pages); https://doi.org/10.1038/s41419-019-1413-8
- H. Y. Wang, X. Lin, G. G. Huang, R. Zhou, S. Y. Lei, J. Ren, K. R. Zhang, C. L. Feng, Y. W. Wu and W. Tang, Atranorin inhibits NLRP3 inflammasome activation by targeting ASC and protects NLRP3 inflammasome-driven diseases, Acta Pharmacol. Sin. 44(8) (2023) 1687–1700; https://doi.org/10.1038/s41401-023-01054-1
- C. Jiang, S. Xie, G. Yang and N. Wang, Spotlight on NLRP3 Inflammasome: Role in pathogenesis and therapies of atherosclerosis, J. Inflamm. Res. 14 (2021) 7143–7172; https://doi.org/10.2147/jir.S344730
- Z. Wan, Y. Fan, X. Liu, J. Xue, Z. Han, C. Zhu, and X. Wang, NLRP3 inflammasome promotes diabetes-induced endothelial inflammation and atherosclerosis, Diabetes Metab. Syndr. Obes. 12 (2019) 1931–1942; https://doi.org/10.2147/dmso.S222053
- L. Qiao, J. Ma, Z. Zhang, W. Sui, C. Zhai, D. Xu, Z. Wang, H. Lu, M. Zhang, C. Zhang, W. Chen and Y. Zhang, Deficient chaperone-mediated autophagy promotes inflammation and atherosclerosis, Circ. Res. 129(12) (2021) 1141–1157; https://doi.org/10.1161/circresaha.121.318908
- M. Takahashi, NLRP3 inflammasome as a key driver of vascular disease, Cardiovasc. Res. 118(2) (2022) 372–385; https://doi.org/10.1093/cvr/cvab010
- Y. Lv, Z. Jiang, W. Zhou, H. Yang, G. Jin, D. Wang, C. Kong, Z. Qian, Y. Gu, S. Chen and L. Zhu, Low-shear stress promotes atherosclerosis via inducing endothelial cell pyroptosis mediated by IKKε/STAT1/NLRP3 pathway, Inflammation 47(3) (2024) 1053–1066; https://doi.org/10.1007/s10753-023-01960-w
- Z. Peng, H. Zhan, Y. Shao, Y. Xiong, L. Zeng, C. Zhang, Z. Liu, Z. Huang, H. Su and Z. Yang, 13-Methylberberine improves endothelial dysfunction by inhibiting NLRP3 inflammasome activation via autophagy induction in human umbilical vein endothelial cells, Chin. Med. 15 (2020) Article ID 8 (12 pages); https://doi.org/10.1186/s13020-020-0286-1
- M. J. M. Silvis, E. J. Demkes, A. T. L. Fiolet, M. Dekker, L. Bosch, G. P. J. van Hout, L. Timmers and D. P. V. de Kleijn, Immunomodulation of the NLRP3 inflammasome in atherosclerosis, coronary artery disease, and acute myocardial infarction, J. Cardiovasc. Transl. Res. 14(1) (2021) 23–34; https://doi.org/10.1007/s12265-020-10049-w
- J. Ye, L. Li, M. Wang, Q. Ma, Y. Tian, Q. Zhang, J. Liu, B. Li, B. Zhang, H. Liu and G. Sun, Diabetes mellitus promotes the development of atherosclerosis: The role of NLRP3, Front. Immunol. 13 (2022) Article ID 900254 (12 pages); https://doi.org/10.3389/fimmu.2022.900254
- S. Paik, J. K. Kim, P. Silwal, C. Sasakawa and E. K. Jo, An update on the regulatory mechanisms of NLRP3 inflammasome activation, Cell. Mol. Immunol. 18(5) (2021) 1141–1160; https://doi.org/10.1038/s41423-021-00670-3
- N. Kelley, D. Jeltema, Y. Duan and Y. He, The NLRP3 inflammasome: An overview of mechanisms of activation and regulation, Int. J. Mol. Sci. 20(13) (2019) Article ID 3328 (24 pages); https://doi.org/10.3390/ijms20133328
- L. Luo, F. Wang, X. Xu, M. Ma, G. Kuang, Y. Zhang, D. Wang, W. Li, N. Zhang, K. Zhao, STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation, Exp. Mol. Med. 56(9) (2024) 1980–1990; https://doi.org/10.1038/s12276-024-01298-9
- Z. Xu, Z. M. Chen, X. Wu, L. Zhang, Y. Cao and P. Zhou, Distinct molecular mechanisms underlying potassium efflux for nlrp3 inflammasome activation, Front. Immunol. 11 (2020) Article ID 609441 (7 pages); https://doi.org/10.3389/fimmu.2020.609441
- X. Chen, X. Guo, Q. Ge, Y. Zhao, H. Mu and J. Zhang, ER stress activates the NLRP3 inflamma-some: A novel mechanism of atherosclerosis, Oxid. Med. Cell. Longev. 2019 (2019) Article ID 3462530 (18 pages); https://doi.org/10.1155/2019/3462530
- L. Chen, W. Zhang, H. Chen, Y. Zhang, B. Guo, L. Yang, C. Yin, Q. Zuo, L. Ren, L. Bai, R. Wang, S. Zhao, E. Liu and W. Wang, HDAC3 activates endothelial NLRP3 inflammasome and promotes atherosclerosis via inhibiting the acetylation of specificity protein 1, Cell Death Differ. 33 (2026) 930–944; https://doi.org/10.1038/s41418-025-01620-6
- D. Liu, X. Zeng, X. Li, C. Cui, R. Hou, Z. Guo, J. L. Mehta and X. Wang, Advances in the molecular mechanisms of NLRP3 inflammasome activators and inactivators, Biochem. Pharmacol. 175 (2020) Article ID 113863 (12 pages); https://doi.org/10.1016/j.bcp.2020.113863
- T. Kodi, R. Sankhe, A. Gopinathan, K. Nandakumar and A. Kishore, New insights on NLRP3 Inflammasome: Mechanisms of activation, inhibition, and epigenetic regulation, J. Neuroimmune Pharmacol. 19(1) (2024) Article ID 7 (26 pages); https://doi.org/10.1007/s11481-024-10101-5
- A. Zahid, B. Li, A. J. K. Kombe, T. Jin and J. Tao, Pharmacological inhibitors of the NLRP3 inflammasome, Front. Immunol. 10 (2019) Article ID 2538 (10 pages); https://doi.org/10.3389/fimmu.2019.02538
- S. Agarwal, J. P. Pethani, H. A. Shah, V. Vyas, S. Sasane, H. Bhavsar, D. Bandyopadhyay, P. Giri, K. Viswanathan, M. R. Jain and R. Sharma, Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor, Bioorg. Med. Chem. Lett. 30(21) (2020) Article ID 127571 (4 pages); https://doi.org/10.1016/j.bmcl.2020.127571
- P. Thapa, S. P. Upadhyay, V. Singh, V. C. Boinpelly, J. Zhou, D. K. Johnson, P. Gurung, E. S. Lee, R. Sharma and M. Sharma, Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors, Eur. J. Med. Chem. Rep. 7 (2023) Article ID 100100 (13 pages); https://doi.org/10.1016/j.ejmcr.2022.100100
- E. Mezzaroma, A. Abbate and S. Toldo, NLRP3 Inflammasome inhibitors in cardiovascular diseases, Molecules 26(4) (2021) Article ID 976 (19 pages); https://doi.org/10.3390/molecules26040976
- S. Moon, S. Muniyappan, S. B. Lee and B. H. Lee, Small-molecule inhibitors targeting proteasome-associated deubiquitinases, Int. J. Mol. Sci. 22(12) (2021) Article ID 6213 (19 pages); https://doi.org/10.3390/ijms22126213
- S. E. Alavi, S. Alharthi, S. Z. Alavi, A. Raza and H. E. Shahmabadi, Bioresponsive drug delivery systems, Drug Discov. Today 29(1) (2024) Article ID 103849; https://doi.org/10.1016/j.drudis.2023.103849
- M. Yang and L. Zhao, The selective NLRP3-inflammasome inhibitor CY-09 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3-inflammasome activation, Curr. Med. Chem. 30(28) (2023) 3261–3270; https://doi.org/10.2174/0929867329666220922104654
- S. Lou, M. Wu and S. Cui, Targeting NLRP3 inflammasome: Structure, function, and inhibitors, Curr. Med. Chem. 31(15) (2024) 2021–2051; https://doi.org/10.2174/0109298673289984231127062528
- S. Kiran, A. Rakib and U. P. Singh, The NLRP3 inflammasome inhibitor dapansutrile attenuates cyclophosphamide-induced interstitial cystitis, Front. Immunol. 13 (2022) Article ID 903834 (13 pages); https://doi.org/10.3389/fimmu.2022.903834
- T. Y. Zhang, X. Y. Chen, X. Y. Duan, Q. R. Zhao, L. Ma, Y. Q. Yan, Y. Wang, T. Liu and S. X. Wang, [Research progress on natural small molecule compound inhibitors of NLRP3 inflammasome], Zhongguo Zhong Yao Za Zhi 50(3) (2025) 644–657; https://doi.org/10.19540/j.cnki.cjcmm.20240828.701
- Z. Yuan, D. Yu, T. Gou, G. Tang, C. Guo and J. Shi, Research progress of NLRP3 inflammasome and its inhibitors with aging diseases, Eur. J. Pharmacol. 957 (2023) Article ID 175931; https://doi.org/10.1016/j.ejphar.2023.175931
- M. Su, W. Wang, F. Liu and H. Li, Recent progress on the discovery of NLRP3 inhibitors and their therapeutic potential, Curr. Med. Chem. 28(3) (2021) 569–582; https://doi.org/10.2174/0929867327666200123093544
- P. Chen and X. Li, NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies, Front. Pharmacol. 15 (2024) Article ID 1430236 (15 pages); https://doi.org/10.3389/fphar.2024.1430236
- O. Beltrán, A. Costa-Santos, M. Luna, O. Abelenda, A. Ogando, A. Topete, J. Juarez, S. Barbosa and P. Taboada, Cell membrane-based nanovesicles as potential drug delivery systems for atherosclerosis therapy, Colloids Surf. B Biointerfaces 257 (2026) Article ID 115190 (15 pages); https://doi.org/10.1016/j.colsurfb.2025.115190.
- Y. Zhang, F. Li, L. Liu, Z. An, H. Luo, H. Zhang, R. Ma, R. Zhang, Q. Dai, M. Zhang, J. Tian, C. Liu, X. Song and Y. Lu, Nanoparticle drug delivery systems for atherosclerosis: Precision targeting, inflammatory modulation, and plaque stabilization, Adv. Sci. 12(36) (2025) e04990 (25 pages); https://doi.org/10.1002/advs.202504990
- P. Karakasis, P. Theofilis, P. K. Vlachakis, K. Grigoriou, D. Patoulias, A. P. Antoniadis and N. Fragakis, Reprogramming atherosclerosis: Precision drug delivery, nanomedicine, and immune-targeted therapies for cardiovascular risk reduction, Pharmaceutics 17(8) (2025) Article ID 1028 (36 pages); https://doi.org/10.3390/pharmaceutics17081028
- D. Nurhidayah, A. Maruf, X. Zhang, X. Liao, W. Wu and G. Wang, Advanced drug-delivery systems: Mechanoresponsive nanoplatforms applicable in atherosclerosis management, Nanomedicine 14(23) (2019) 3105–3122; https://doi.org/10.2217/nnm-2019-0172
- R. Y. Pan, X. X. Kong, Y. Cheng, L. Du, Z. C. Wang, C. Yuan, J. B. Cheng, Z. Q. Yuan, H. Y. Zhang and Y. J. Liao, 1,2,4-Trimethoxybenzene selectively inhibits NLRP3 inflammasome activation and attenuates experimental autoimmune encephalomyelitis, Acta Pharmacol. Sin. 42(11) (2021) 1769–1779; https://doi.org/10.1038/s41401-021-00613-8
- F. P. Kreutzer, A. Meinecke, K. Schmidt, J. Fiedler and T. Thum, Alternative strategies in cardiac preclinical research and new clinical trial formats, Cardiovasc. Res. 118(3) (2022) 746–762; https://doi.org/10.1093/cvr/cvab075
- H. Tang, X. Zou, P. Chen, Y. Wang, S. Gao, T. Wang, Y. Xu and S.-L. Ji, Broxyquinoline targets NLRP3 to inhibit inflammasome activation and alleviate NLRP3-associated inflammatory diseases, Int. Immunopharmacol. 156 (2025) Article ID 114687; https://doi.org/10.1016/j.intimp.2025.114687
- C. T. Vong, H. H. L. Tseng, P. Yao, H. Yu, S. Wang, Z. Zhong and Y. Wang, Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases, Drug Discov. Today 26(6) (2021) 1394–1408; https://doi.org/10.1016/j.drudis.2021.02.018
Language: English
Page range: 1 - 16
Accepted on: May 14, 2026
Published on: Jun 30, 2026
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Ligang Bao, Xialing Dai, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.